Skip to main content
. Author manuscript; available in PMC: 2017 Jan 27.
Published in final edited form as: Small. 2015 Dec 7;12(4):477–487. doi: 10.1002/smll.201501985

Figure 7.

Figure 7

In vivo delivery of NP-siLuc-GPC3 Ab knocks down luminescence of RH7777-Luc-GPC3 tumors. (a) Scheme of tumor implantation and treatment. Two weeks after orthotopic injection with RH7777-Luc-GPC3 cells, xenograft-bearing mice received five daily intravenous injections of NP-siLuc-GPC3 Ab. IVIS imaging was initiated one day prior to the first NP-siLuc-GPC3 Ab injection. (b) Representative live IVIS images of mice bearing RH7777-Luc-GPC3 tumors with administration of NP-siLuc-GPC3 Ab. Untreated mice and mice treated with scramble siRNA served as the controls. (c) Quantitative luminescence of mice from untreated and treated groups (n = 4). Luminescence was normalized to day 0 and line graph was indicated as presented as mean ± SD. Arrows indicate NP-siRNA-GPC3 Ab injection.